|
1
|
Jemal A, Bray F, Center MM, Ferlay J, et
al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
View Article : Google Scholar
|
|
2
|
Clifford GM, Smith JS, Plummer M, et al:
Human papillomavirus types in invasive cervical cancer worldwide: a
meta-analysis. Br J Cancer. 88:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quek SC, Lim BK, Domingo E, et al: Human
papillomavirus type distribution in invasive cervical cancer and
high-grade cervical intraepithelial neoplasia across 5 countries in
Asia. Int J Gynecol Cancer. 23:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown DR, Kjaer SK, Sigurdsson K, et al:
The impact of quadrivalent human papillomavirus (HPV; types 6, 11,
16, and 18) L1 virus-like particle vaccine on infection and disease
due to oncogenic nonvaccine HPV types in generally HPV-naive women
aged 16–26 years. J Infect Dis. 199:926–935. 2009.PubMed/NCBI
|
|
5
|
Kemp TJ, Hildesheim A, Safaeian M, et al:
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that
may mediate cross-protection. Vaccine. 29:2011–2014. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen CH, Wang TL, Hung CF, et al: Boosting
with recombinant vaccinia increases HPV-16 E7-specific T cell
precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Vaccine. 18:2015–2022. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brinkman JA, Xu X and Kast WM: The
efficacy of a DNA vaccine containing inserted and replicated
regions of the E7 gene for treatment of HPV-16 induced tumors.
Vaccine. 25:3437–3444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eiben GL, Velders MP, Schreiber H, et al:
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor
model to determine the efficacy of vaccination strategies in
HLA-A*0201 transgenic mice. Cancer Res. 62:5792–5799. 2002.
|
|
9
|
Ohlschlager P, Pes M, Osen W, et al: An
improved rearranged human papillomavirus type 16 E7 DNA vaccine
candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell
response. Vaccine. 24:2880–2893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gurunathan S, Klinman DM and Seder RA: DNA
vaccines: immunology, application, and optimization. Annu Rev
Immunol. 18:927–974. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CH, Wang TL, Hung CF, et al:
Enhancement of DNA vaccine potency by linkage of antigen gene to an
HSP70 gene. Cancer Res. 60:1035–1042. 2000.PubMed/NCBI
|
|
12
|
Li Y, Subjeck J, Yang G, et al: Generation
of anti-tumor immunity using mammalian heat shock protein 70 DNA
vaccines for cancer immunotherapy. Vaccine. 24:5360–5370. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hauser H, Shen L, Gu QL, et al: Secretory
heat-shock protein as a dendritic cell-targeting molecule: a new
strategy to enhance the potency of genetic vaccines. Gene Ther.
11:924–932. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Milani V, Noessner E, Ghose S, et al: Heat
shock protein 70: role in antigen presentation and immune
stimulation. Int J Hyperthermia. 18:563–575. 2002.PubMed/NCBI
|
|
15
|
Li Z, Menoret A and Srivastava P: Roles of
heat-shock proteins in antigen presentation and cross-presentation.
Curr Opin Immunol. 14:45–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bendz H, Ruhland SC, Pandya MJ, et al:
Human heat shock protein 70 enhances tumor antigen presentation
through complex formation and intracellular antigen delivery
without innate immune signaling. J Biol Chem. 282:31688–31702.
2007. View Article : Google Scholar
|
|
17
|
Udono H, Ichiyanagi T, Mizukami S, et al:
Heat shock proteins in antigen trafficking - implications on
antigen presentation to T cells. Int J Hyperthermia. 25:617–625.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Srivastava P: Interaction of heat shock
proteins with peptides and antigen presenting cells: chaperoning of
the innate and adaptive immune responses. Annu Rev Immunol.
20:395–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osterloh A and Breloer M: Heat shock
proteins: linking danger and pathogen recognition. Med Microbiol
Immunol. 197:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Binder RJ and Srivastava PK: Peptides
chaperoned by heat-shock proteins are a necessary and sufficient
source of antigen in the cross-priming of CD8+ T cells.
Nat Immunol. 6:593–599. 2005.PubMed/NCBI
|
|
21
|
Massa C, Guiducci C, Arioli I, et al:
Enhanced efficacy of tumor cell vaccines transfected with
secretable hsp70. Cancer Res. 64:1502–1508. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murshid A, Gong J, Stevenson MA, et al:
Heat shock proteins and cancer vaccines: developments in the past
decade and chaperoning in the decade to come. Expert Rev Vaccines.
10:1553–1568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zong J, Peng Q, Wang Q, et al: Human HSP70
and modified HPV16 E7 fusion DNA vaccine induces enhanced specific
CD8+ T cell responses and anti-tumor effects. Oncol Rep.
22:953–961. 2009.PubMed/NCBI
|
|
24
|
Trimble CL, Peng S, Kos F, et al: A phase
I trial of a human papillomavirus DNA vaccine for HPV16+
cervical intraepithelial neoplasia 2/3. Clin Cancer Res.
15:361–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang QY, Xu YF, Fan DS, et al: Linkage of
modified human papillomavirus type 16 E7 to CD40 ligand
enhances specific CD8+T-lymphocyte induction and
anti-tumour activity of DNA vaccine. Zhongguo Yi Xue Ke Xue Yuan
Xue Bao. 29:584–591. 2007.(In Chinese).
|
|
26
|
Feltkamp MC, Smits HL, Vierboom MP, et al:
Vaccination with cytotoxic T lymphocyte epitope-containing peptide
protects against a tumor induced by human papillomavirus type
16-transformed cells. Eur J Immunol. 23:2242–2249. 1993. View Article : Google Scholar
|
|
27
|
Tindle RW, Fernando GJ, Sterling JC, et
al: A ‘public’ T-helper epitope of the E7 transforming protein of
human papillomavirus 16 provides cognate help for several E7 B-cell
epitopes from cervical cancer-associated human papillomavirus
genotypes. Proc Natl Acad Sci USA. 88:5887–5891. 1991.
|
|
28
|
Hsu KF, Hung CF, Cheng WF, et al:
Enhancement of suicidal DNA vaccine potency by linking
Mycobacterium tuberculosis heat shock protein 70 to an
antigen. Gene Ther. 8:376–383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Wu BH, Rowse GJ, et al: Induction
of CD4-independent E7-specific CD8+ memory response by
heat shock fusion protein. Clin Vaccine Immunol. 14:1013–1023.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang Q, Richmond JF, Suzue K, et al: In
vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock
protein 70 fusion proteins maps to a discrete domain and is
CD4+ T cell independent. J Exp Med. 191:403–408. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Delneste Y, Magistrelli G, Gauchat J, et
al: Involvement of LOX-1 in dendritic cell-mediated antigen
cross-presentation. Immunity. 17:353–362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saito K, Dai Y and Ohtsuka K: Enhanced
expression of heat shock proteins in gradually dying cells and
their release from necrotically dead cells. Exp Cell Res.
310:229–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang MH, Grossmann ME and Young CY: Forced
expression of heat-shock protein 70 increases the secretion of
Hsp70 and provides protection against tumour growth. Br J Cancer.
90:926–931. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mambula SS, Stevenson MA, Ogawa K, et al:
Mechanisms for Hsp70 secretion: crossing membranes without a
leader. Methods. 43:168–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Broquet AH, Thomas G, Masliah J, et al:
Expression of the molecular chaperone Hsp70 in detergent-resistant
microdomains correlates with its membrane delivery and release. J
Biol Chem. 278:21601–21606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lancaster GI and Febbraio MA:
Exosome-dependent trafficking of HSP70: a novel secretory pathway
for cellular stress proteins. J Biol Chem. 280:23349–23355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Srivastava PK, Udono H, Blachere NE, et
al: Heat shock proteins transfer peptides during antigen processing
and CTL priming. Immunogenetics. 39:93–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Srivastava PK and Udono H: Heat shock
protein-peptide complexes in cancer immunotherapy. Curr Opin
Immunol. 6:728–732. 1994. View Article : Google Scholar : PubMed/NCBI
|
